In Other News

• Tumor and Immune Biomarkers Linked to Treatment Response in T-Cell Lymphoma

• Prototype Point-of-Care Lateral Flow Test Aims to Improve Neonatal Sepsis Triage

• Blood MRD Testing Aids Risk Analysis in Bladder and Other Cancers

• CE-Marked IVD Sequencing Platform Launches Across Ten EU Countries

• Liquid Biopsy Measures Tumor Burden and Identifies Small Cell Lung Cancer Subtypes

• Rapid Lab-Free UTI Test Enters First Use in Care Home Setting

• Genetic Testing Identifies Undiagnosed Carriers of Sickle Cell and Thalassemia

• Prototype Point-of-Care Lateral Flow Test Aims to Improve Neonatal Sepsis Triage

• CE-Marked IVD Sequencing Platform Supports IVDR-Compliant Diagnostic Workflows in Europe

• Rapid Lab-Free UTI Test Enters First Use in Care Home Setting

• Microfluidic Assay Predicts Treatment Response in Pediatric Leukemia

• Blood-Based Small RNA Assay Predicts Survival After Lung Cancer Treatment

• AI Models Use Routine Blood Tests and Health Records to Predict Cancer Risk

• AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification

• Donor-Derived DNA Testing May Reduce Biopsies in Kidney Transplant Monitoring

• Spinal Fluid Liquid Biopsy May Help Clarify Uncertain Brain Tumor Findings

• Immune and Inflammatory Markers May Help Assess CAR T-Cell Complication Risk

• Roche Launches Automated Test to Support Mesothelioma Differential Diagnosis

• New NGS Panel Detects AML Fusions at MRD-Level Sensitivity

• Blood Proteins Linked to Mortality Risk and Biological Aging Across Organ Systems

• COVID-19 and Flu Combo Test Launches With FDA Clearance

• Two-Step Blood Test Improves Specificity for Alzheimer’s Diagnosis

• Compact Immunoanalyzer Gains CE Mark for Testing Across Local Care Settings